Has the Hong Kong Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the Hong Kong Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 11.5x which is lower than its 3-year average PE of 23.5x. The 3-year average PS ratio of 1.7x is higher than the industry's current PS ratio of 1.2x.

How does Hong Kong Pharma compare with similar industries?

There is insufficient data on the sub-industries of this industry.

Hong Kong (HSI) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 11 Aug 2022	HK$582.4b	HK$512.8b	HK$51.9b	7.5x	11.2x	1.1x
Sat, 09 Jul 2022	HK$658.1b	HK$514.7b	HK$52.2b	8.9x	12.6x	1.3x
Mon, 06 Jun 2022	HK$565.5b	HK$515.9b	HK$52.1b	8.8x	10.8x	1.1x
Wed, 04 May 2022	HK$577.6b	HK$516.4b	HK$51.8b	8.2x	11.2x	1.1x
Fri, 01 Apr 2022	HK$646.4b	HK$523.8b	HK$47.3b	8.4x	13.7x	1.2x
Sun, 27 Feb 2022	HK$650.5b	HK$499.3b	HK$44.1b	9.8x	14.7x	1.3x
Tue, 25 Jan 2022	HK$715.1b	HK$497.7b	HK$43.9b	9.6x	16.3x	1.4x
Thu, 23 Dec 2021	HK$699.1b	HK$496.9b	HK$43.8b	9.4x	16x	1.4x
Sat, 20 Nov 2021	HK$693.2b	HK$495.7b	HK$43.4b	9.4x	16x	1.4x
Mon, 18 Oct 2021	HK$730.1b	HK$490.8b	HK$42.6b	10.2x	17.2x	1.5x
Wed, 15 Sep 2021	HK$771.9b	HK$489.5b	HK$42.4b	11.1x	18.2x	1.6x
Fri, 13 Aug 2021	HK$873.9b	HK$489.5b	HK$42.4b	11.9x	20.6x	1.8x
Tue, 08 Jun 2021	HK$1.1t	HK$463.7b	HK$30.0b	15.3x	36.1x	2.3x
Mon, 01 Mar 2021	HK$953.9b	HK$439.3b	HK$27.7b	12.4x	34.4x	2.2x
Thu, 03 Dec 2020	HK$843.3b	HK$424.8b	HK$25.2b	15x	33.5x	2x
Sun, 06 Sep 2020	HK$853.8b	HK$407.8b	HK$27.1b	17.1x	31.5x	2.1x
Wed, 10 Jun 2020	HK$728.0b	HK$416.7b	HK$27.5b	14.6x	26.5x	1.7x
Tue, 03 Mar 2020	HK$720.7b	HK$429.4b	HK$27.1b	14x	26.6x	1.7x
Fri, 06 Dec 2019	HK$672.5b	HK$416.3b	HK$34.1b	11.8x	19.7x	1.6x
Mon, 09 Sep 2019	HK$720.7b	HK$414.0b	HK$34.7b	11.9x	20.7x	1.7x


HK Market	-0.65%
Healthcare	-1.61%
Pharma	0.85%
Pharma	0.85%

Company	Last Price	7D	1Y	Valuation
1093 CSPC Pharmaceutical Group	HK$8.55	4.3% +HK$4.2b	-22.1%	PE15.8x
867 China Medical System Holdings	HK$12.82	8.8% +HK$2.6b	-24.8%	PE8.9x
3692 Hansoh Pharmaceutical Group	HK$16.10	1.8% +HK$1.7b	-37.2%	PE30.1x
1177 Sino Biopharmaceutical	HK$4.47	1.4% +HK$1.1b	-32.9%	PE4.9x
6185 CanSino Biologics	HK$65.15	6.8% +HK$1.0b	-78.5%	PE6.7x

Jul 28

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited announced that Mr. Li Yi has resigned as an executive director and the Chief Executive Officer of the Company, as he wishes to focus on other business development, with effect from 28 July 2022. Mr. Li will be engaged as a senior consultant of the Company on the same date. The Board further announces that with effect from 28 July 2022, Mr. Tse, Eric S Y ("Mr. Tse") has been appointed as the Chief Executive Officer of the Company. Mr. Tse is an executive director and a substantial shareholder of the Company. The biographical details of Mr. Tse and his relationship with any directors, substantial or controlling shareholders and senior management of the Company, if any, can be found in the 2021 annual report of the Company. He did not hold any directorship in other listed companies in the past three years. Mr. Tse, Eric S Y, the new Chief Executive Officer, has been serving as a director of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd. since 2019 and the president of CT Tianqing since July 2020. Under the leadership of Mr. Tse, CT Tianqing has continued to promote the three strategies of "Comprehensive Innovation, Digital Transformation and Talent Strategy", with many achievements have been made. In terms of innovation and research and development through its two-wheeled approach of independent R&D and in-depth collaboration, CT Tianqing has procured business development of a number of blockbuster innovative drugs through collaboration, and achieved a qualitative breakthrough in its own innovation transformation with increasing share of innovative drugs in its independent R&D pipeline and significant growth in revenue contribution from innovative drugs, which resulted in comprehensive acceleration in internationalization layout and steady growth in performance. At the same time, CT Tianqing actively promotes corporate digital transformation to achieve lean operations, efficiency enhancement and quick adaptability to environmental changes. In terms of talent strategy, CT Tianqing vigorously promotes the optimization of its organisation and talent resources by bringing in domestic and overseas management teams, nurturing internal core talents, taking stock of internal talents, and establishing an equity incentive mechanism so as to secure a source of momentum for the organization's development. After taking over as Chief Executive Officer, Mr. Tse will be responsible for the day-to-day business activities and the decision-making on major issues including corporate strategy, appointment and removal of personnel, and investment and integration, around Sino Biopharm's four key strategies of "Integration, Innovation, Globalization and Digitalization"; the overall management of the Company's subsidiaries; and the establishment of professional management teams to further enhance organizational efficiency, drive business innovation, connect with external collaboration, and promote innovation at a global level. The new management will closely follow the four core strategic directions of Sino Biopharm to strengthen its business, of which, Ms. Tse, Theresa Y Y, the chairwoman of the Board, will focus on the strategic planning, international business, capital market operations of the Group and the listed company- related matters, while Mr. Tse, Eric S Y, the Chief Executive Officer, will focus on the operations management, organizational optimization and efficiency enhancement of all subsidiaries under the listed company. With their respective roles, the chairwoman of the Board and the Chief Executive Officer will lead Sino Biopharm's drive to innovate and continue to create value for patients, shareholders and the society.

Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

512

First half 2022 earnings released

867

China Medical System Holdings Limited to Report First Half, 2022 Results on Aug 22, 2022

6600

SciClone Pharmaceuticals (Holdings) Limited to Report Q2, 2022 Results on Aug 18, 2022

874

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited to Report First Half, 2022 Results on Aug 19, 2022

6996

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

3613

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2022 Results on Aug 12, 2022

2552

We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

1093

CSPC Pharmaceutical Group Announces Resignation of Wu Guizhen as Independent Non-Executive Director

6185

Investor sentiment deteriorated over the past week

1177

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

3320

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

570

China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Analysts Just Cut Their EPS Forecasts Substantially

1666

Is Tong Ren Tang Technologies Co. Ltd. (HKG:1666) Trading At A 43% Discount?

3692

Investor sentiment improved over the past week

3737

Chairman recently bought HK$177k worth of stock

2877

Full year 2021 earnings: EPS misses analyst expectations